The release of the long-awaited outcomes trial for Sanofi/Regeneron Pharmaceuticals Inc.'s PCSK9 inhibitor at the American College of Cardiology Scientific Sessions was a big news event for the cholesterol-lowering field, but the announcement that the firms will lower the price of Praluent (alirocumab) in the US in line with a recommendation from the Institute for Clinical and Economic Review (ICER) stands out for the potential to set a precedent for the pharmaceutical industry.
The two drug partners announced March 10 they would lower the price of Praluent to a level ICER deemed cost...






